Form 4: Kura Oncology's Chief Legal Officer, Teresa Brophy Bair, Reports Acquisition of Stock and Options

Teresa Brophy Bair, Chief Legal Officer of Kura Oncology, reports the acquisition of restricted stock units and options in Kura Oncology.

Summary

• On January 2, 2025, Teresa Brophy Bair, the Chief Legal Officer of Kura Oncology, acquired 46,250 shares of common stock and an option to purchase 92,500 shares of common stock.
• The common stock was acquired through a grant of Restricted Stock Units (RSUs) at a price of $0.
• These RSUs vest in four equal annual installments starting January 26, 2026, and continuing on January 26, 2027, January 26, 2028, and January 26, 2029.
• The option to purchase common stock has an exercise price of $8.68 and vests in 48 equal monthly installments commencing on the grant date, with an expiration date of January 1, 2035.
• Following these transactions, Ms. Bair directly owns 115,229 shares of Kura Oncology common stock and options to purchase 92,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option grants to an executive, which is neither particularly positive nor negative on its own.

Positives

• The acquisition of RSUs and options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders. These filings are common across all publicly traded companies and are a regular part of the financial landscape.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of compensation for executives in the biotechnology industry, used to incentivize performance and align interests with shareholders.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and RSUs as part of their executive compensation packages.
• The vesting schedules and exercise prices are generally in line with industry standards for similar-sized companies in the biotech sector.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the Chief Legal Officer.

Key Dates